FDA label
What is Kevzara used for?
Kevzara contains sarilumab. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label for Kevzara lists 3 uses: Rheumatoid Arthritis (RA); Polymyalgia Rheumatica (PMR); Polyarticular Juvenile Idiopathic Arthritis (pJIA).
Run it in Rivvi
Which 2027 plans near you dropped or restricted Kevzara?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Kevzara, injection, solution
Indications and Usage, quoted from the label by Sanofi-Aventis U.S. LLC (BLA761037). Cross-references to other label sections are left out.
Rheumatoid Arthritis (RA)
KEVZARA® is indicated for treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).
Polymyalgia Rheumatica (PMR)
KEVZARA is indicated for treatment of adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.
Polyarticular Juvenile Idiopathic Arthritis (pJIA)
KEVZARA is indicated for treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh 63 kg or greater.
Source: DailyMed label, set id 827bc01c-d379-4266-a18c-c7f904b76af3, version 15, effective February 27, 2026. NDC 0024-5908, one of 4 listings for this product.
Questions
What is Kevzara used for?
The FDA label for Kevzara lists 3 uses: Rheumatoid Arthritis (RA); Polymyalgia Rheumatica (PMR); Polyarticular Juvenile Idiopathic Arthritis (pJIA).
What drug class is Kevzara?
FDA lists sarilumab in the Interleukin-6 Receptor Antagonist established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.